Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages - 2Enormous Credit And All that You Really want To Be aware
- 3Israeli strikes in Gaza kill 25 people, Hamas health authority says
- 4How did birds survive while dinosaurs went extinct?
- 5From Modesty to Administration: Self-improvement in Interactive abilities
- Pick Your Favored sort of cooking
- Why doing good also makes us feel good, during the holidays and beyond
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- Jenny & Dave Marrs Mourn Loss of Former ‘Fixer to Fabulous: Italiano’ Guest
- Top German court to rule on claims by Wirecard shareholders
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- The Force of Positive Reasoning: Day to day Attestations
- Israel says Iran's military industry will be destroyed 'within days'
- Which Kind of Pet Makes the Incomparable Buddy?
